The developer of the very first approved Covid 19 antibody cocktail in China said that the lab tests found a treatment that is holding up well against the new Omicron variant.
SCMP.com notes that one of the antibodies had a “substantial drop in activity”.
Brii Biosciences said its therapy “retains activity” against major coronavirus strains including the highly transmissible Delta variant and its sub-lineage Delta Plus.
China approves treatment
China’s medical products regulator approved its use recently and the company said the treatment had shown an 80 per cent reduction in hospital admissions and deaths during a global phase 3 clinical trial with 847 non-hospitalized Covid-19 patients. It said no serious adverse events were identified.
The company said while one of the antibodies showed “a substantial drop in activity” against Omicron in tests by independent laboratories, the other one “was not impacted” by the highly mutated variant.
“The Omicron variant remains susceptible to neutralisation by the … combination,” Brii Bio said.
“Together, the combination therapy retains neutralising activity against the Omicron variant.”
Fauci drops bomb news about booster shots
It’s been reported that Fauci made the statement on Sunday morning and said that the level of protection that the current coronavirus booster shots give to individuals would have to be monitored closely over the next several months.
“If it becomes necessary to get yet another boost, then we’ll just have to deal with it when that occurs,” Fauci said.
It’s been also revealed that the National Institute of Allergy and Infectious Diseases director also said that he’s “hoping” that a third mRNA shot will give longer-lasting protection.
“I’m hoping from an immunological standpoint that that third shot of an mRNA and the second shot of a J&J will give a much greater durability of protection than just the six months or so that we’re seeing right now,” Fauci said.
Stay tuned for more news.
